Results 101 to 110 of about 99,136 (277)

Cost of the treatment of myelodisplastic syndrome in Brazil

Revista Brasileira de Hematologia e Hemoterapia, 2011
INTRODUCTION: Myelodysplastic syndrome is an incurable and rare hematological disease that affects the production of blood cells. One aim of treatment is to maintain the blood-cell count to near-normal levels.
Otávio Clark, Enéas José de Matos Faleiros   +1 more
doaj   +1 more source

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. [PDF]

, 2009
Progress in the management of patients with myelodysplastic syndromes (MDS) has been hampered by the inability to detect cytogenetic abnormalities in 40-60% of cases.
Bueso-Ramos, CE, Estey, EH, Garcia-Manero, G, Gilliland, DG, Heinrichs, S, Issa, J-P, Kantarjian, HM, Kornblau, SM, Kulkarni, RV, Levine, RL, Li, C, Loh, ML, Look, AT, Neuberg, D   +13 more
core   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Myelodysplasia followed by Good's Syndrome: A unique manifestation associated with thymoma

Kaohsiung Journal of Medical Sciences, 2012
Good’s syndrome, also known as thymoma with combined immunodeficiency, is rare. The immunodeficiency may precede, arise concurrently with or follow the diagnosis of thymoma.
Ling-Ping Chen, Jui-Shan Tsai, Wei-Ming Lai, Ling-Jung Yen, Ming-Sun Yu, Shyh-Jer Lin   +5 more
doaj   +1 more source

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation

Haematologica, 2009
Background After successful treatment of malignant diseases, therapy-related myelodysplastic syndrome and acute myeloid leukemia have emerged as significant problems.Design and Methods The aim of this study was to investigate outcome and risk factors in ...
Nicolaus Kröger, Ronald Brand, Anja van Biezen, Axel Zander, Judith Dierlamm, Dietger Niederwieser, Agnès Devergie, Tapani Ruutu, Jackie Cornish, Per Ljungman, Alois Gratwohl, Catherine Cordonnier, Dietrich Beelen, Eric Deconinck, Argiris Symeonidis, Theo de Witte, for the Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)   +16 more
doaj   +1 more source

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome [PDF]

, 2016
Background The EUMDS registry is an unique prospective, longitudinal observational registry enrolling newly diagnosed patients with lower‐risk myelodysplastic syndrome (MDS) from 17 European countries from both university hospitals and smaller regional ...
Austin, Balleari, Bernasconi, Cheson, Cole, Germing, Goldberg, Greenberg, Greenberg, Greenberg, Hellström-Lindberg, Hellström-Lindberg, Jädersten, Jädersten, Kelaidi, Killick, Malcovati, Nilsson-Ehle, Oliva, Park, Park, Schemper, Swart   +22 more
core   +2 more sources

Machine Learning‐Based Prediction of Life‐Threatening Complications During Hemodialysis in Hospitalized Patients With Poor General Conditions

Artificial Organs, EarlyView.
A machine learning model using predialysis data predicted sudden events during or after hemodialysis with high accuracy (auROC: 0.889). The key predictors included emergency hospitalization, recent surgery, high heart rate, low albumin levels, and high CRP.
Naotaka Kato, Takeshi Goto, Tomoyuki Ohira, Hirotaka Kinoshita, Kugo Kurokawa, Kouhei Naganuma, Chikako Ohminato, Junko Ogasawara, Shingo Hatakeyama, Yoshihiro Sasaki, Kazuyoshi Hirota, Chikara Ohyama   +11 more
wiley   +1 more source

Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome

Haematologica, 2013
We examined whether lenalidomide exposure up-regulates miRNAs and mRNAs, previously shown to play a role in the disease phenotype of del(5q) myelodysplastic syndrome, in pre-treatment CD34+ marrow cells.
Christopher P. Venner, Joanna Wegrzyn Woltosz, Thomas J. Nevill, H. Joachim Deeg, Gisela Caceres, Uwe Platzbecker, Bart L. Scott, Lubomir Sokol, Sandy Sung, Alan F. List, Aly Karsan   +10 more
doaj   +1 more source

Pediatric Myelodysplastic Syndromes [PDF]

Journal of Hematopathology, 2015
Pediatric myelodysplastic syndromes (MDS) are a group of rare clonal hematopoietic stem cell disorders characterized by varying degree of cytopenias, ineffective and dysplastic hematopoiesis, and the risk of leukemic transformation. The clinical, laboratory, and histologic presentation of pediatric MDS shares significant overlap with other inherited ...
openaire   +1 more source

The diagnostic performance of the basic versus the detailed telomere Flow FISH test in young patients with aplastic anaemia

British Journal of Haematology, EarlyView.
Summary Identifying telomere biology disorders (TBDs) in patients with aplastic anaemia (AA) is essential for guiding appropriate care. Telomere length (TL) measurement by flow cytometry with fluorescence in situ hybridization supports diagnosis, but the real‐world performance of the basic test (lymphocytes and granulocytes) versus the detailed test ...
Nicholas F. DeCleene, Duc T. Nguyen, Susan E. Kirk, Hannah L. Helber, Ghadir S. Sasa, Alison A. Bertuch   +5 more
wiley   +1 more source